Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Terranova

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Annals of Internal Medicine|April 1, 1979
Sporadic community-acquired Legionnaires' disease in the United States. A case-control studyG Storch, W B Baine, D W Fraser, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2004
Synthesis and activity of 2-[4-(4-[3H]-2-cyanophenyl)piperazinyl]-N-(2,4,6-[3H]3-3-methylphenyl)acetamide: a selective dopamine D4 receptor agonist and radioligandMark A Matulenko, Bruce Surber, Leimin Fan, et al.
Biochemical Pharmacology|July 28, 2004
Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through Galpha(qo5)Robert B Moreland, Masaki Nakane, Diana L Donnelly-Roberts, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2003
Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphineGin C Hsieh, Peter R Hollingsworth, Brenda Martino, et al.
Neuropharmacology|July 5, 2005
2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonistMasaki Nakane, Marlon D Cowart, Gin C Hsieh, et al.
Giornale Italiano Di Cardiologia|June 15, 1999
[The management of syncope in the hospital: the OESIL Study (Osservatorio Epidemiologico della Sincope nel Lazio)]F Ammirati, F Colivicchi, G Minardi, et al.
Journal of Medicinal Chemistry|April 16, 2004
Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuningAndrew O Stewart, Marlon D Cowart, Robert B Moreland, et al.
Journal of Medicinal Chemistry|August 18, 2006
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunctionTeodozyj Kolasa, Mark A Matulenko, Ahmed A Hakeem, et al.
Journal of Medicinal Chemistry|July 9, 2004
Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunctionMarlon Cowart, Steven P Latshaw, Pramila Bhatia, et al.
Journal of Medicinal Chemistry|December 8, 2006
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunctionMeena V Patel, Teodozyj Kolasa, Kathleen Mortell, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Annals of Internal Medicine|April 1, 1979
Sporadic community-acquired Legionnaires' disease in the United States. A case-control studyG Storch, W B Baine, D W Fraser, et al.
Bioorganic & Medicinal Chemistry Letters|September 24, 2004
Synthesis and activity of 2-[4-(4-[3H]-2-cyanophenyl)piperazinyl]-N-(2,4,6-[3H]3-3-methylphenyl)acetamide: a selective dopamine D4 receptor agonist and radioligandMark A Matulenko, Bruce Surber, Leimin Fan, et al.
Biochemical Pharmacology|July 28, 2004
Comparative pharmacology of human dopamine D(2)-like receptor stable cell lines coupled to calcium flux through Galpha(qo5)Robert B Moreland, Masaki Nakane, Diana L Donnelly-Roberts, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 22, 2003
Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphineGin C Hsieh, Peter R Hollingsworth, Brenda Martino, et al.
Neuropharmacology|July 5, 2005
2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonistMasaki Nakane, Marlon D Cowart, Gin C Hsieh, et al.
Giornale Italiano Di Cardiologia|June 15, 1999
[The management of syncope in the hospital: the OESIL Study (Osservatorio Epidemiologico della Sincope nel Lazio)]F Ammirati, F Colivicchi, G Minardi, et al.
Journal of Medicinal Chemistry|April 16, 2004
Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuningAndrew O Stewart, Marlon D Cowart, Robert B Moreland, et al.
Journal of Medicinal Chemistry|August 18, 2006
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunctionTeodozyj Kolasa, Mark A Matulenko, Ahmed A Hakeem, et al.
Journal of Medicinal Chemistry|July 9, 2004
Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunctionMarlon Cowart, Steven P Latshaw, Pramila Bhatia, et al.
Journal of Medicinal Chemistry|December 8, 2006
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunctionMeena V Patel, Teodozyj Kolasa, Kathleen Mortell, et al.
Pageof 4